36 results about "Tumour invasion" patented technology

The invention discloses an in vitro model simulating human tumor metastasis. Cells in the model have a tumor high metastasis character. The model is constructed by building of a micro spherical hydrogel support frame by tumor high metastasis cells, building of a tumor cell in vitro metastasis model and identifying of the constructed tumor cell in vitro metastasis model. The model can grow in a three-dimensional culturing cell in a clustering mode, and tumor cell biological behaviors in metastasis can be detected. The model has important value in studying of a clinical tumor metastasis mechanism and controlling of screening of metastasis medicine and can be taken as a technical platform for manufacturing anti-tumor metastasis gene vaccines and building screening of anti-tumor metastasis medicine.

The present invention discloses the tumor invasion and metastasis resisting function and application of venin cysteine proteinase inhibitor, and belongs to the field of biomedicine. Through designing and synthesizing sv-Cystatin cDNA according to 99 amino acid sequences of Chinese cobra venin Cystatin protein, cloning to pPICZ alphaA vector and transforming Pichia yeast, stable and high expression engineering bacterium GS115-sv-Cystatin is screened out. Through further inducing expression and purification, the extracorporeal bioactivity experiment shows that the recombinant sv-Cystatin protein has the functions of inhibiting the activity of papain and inhibiting the tumor cell invasion and metastasis obviously, and so do the intracorporeal experiment. The present invention also constitutes pcDNA-sv-Cystatin eukaryotic expression vector. The present invention has huge application foreground in preventing and treating tumor.

The present invention is based on the finding that the level of KIR expression in a cancer cell is significant with regard to tumor invasion and metastasis. Therefore, the present invention concerns methods and compositions for evaluating cancer in a patient based on KIR protein or mRNA expression. The invention also provides methods and compositions for treating cancer using a KIR inhibitor and methods of screening for KIR inhibitors.

The invention relates to a visualization method for quantifying glioma invasiveness based on a kernel density function, which is a method for quantifying glioblastoma invasiveness established by usinga kernel density estimation algorithm on the basis of Image J software and an R language platform. According to the method, a nuclear density estimation graph of cell nucleus distribution is deducedby utilizing a nuclear density estimation algorithm packaged by an R language ggplot2 packet and an MASS packet and a visualization function. The method can help to effectively judge the invasion condition of the tumor from the pathological section in scientific research work, the tumor nuclear density of each region is counted by utilizing the nuclear density, the invasion trend of the tumor canbe roughly judged from a visual graph, and the tumor invasion ability is reflected from the section.

The invention discloses a method for predicting malignant tumor metastasis and invasion capacity in vitro, which comprises the following steps of: (a) extracting DNA (Deoxyribonucleic Acid) from surgical incisal margins or tumor-adjacent tissues; (b) detecting the methylating degree of cytimidine in 5'- end CpG island of seroreaction factor gene DNA sequence in DNA obtained in the step (a); and (c) when the seroreaction factor gene DNA sequence with methylated cytimidine in the 5'-end CpG island is detected in the step (b), presuming that the tissue being detected has the capacity of resisting malignant tumor metastasis and invasion. The invention also provides four artificial nucleotide fragments. The inventor of the invention, for the first time, find that the metastasis and invasion capacity of malignant tumors can be rapidly and accurately predicted by detecting whether the seroreaction factor gene DNA sequence with methylated cytimidine in CpG island exists or not in the tissue being detected. Besides, the nucleotide fragments provided in the invention can be used for accurately and rapidly detecting the methylation of cytimidine in the CpG island in the seroreaction factor gene DNA sequence.

The invention discloses application of valproic acid in preparation of a multidrug resistance reversal agent of a lung cancer resistance medicine, and further discloses application of the valproic acid in the preparation of chemotherapeutics sensitizer of lung cancer resistance and a multidrug resistance tumor invasion resisting and transferring medicine. The application of the valproic acid in the preparation of the multidrug resistance reserval agent of the lung cancer resistance medicine verifies that valproic acid has significant function of a cisplatin persister of human lung cancer resistance through experiments, and verifies that the valproic acid can significantly change drug tolerance of a human lung cancer cell to the cisplatin, improve sensitivity of the human lung cancer cell to the cisplatin, and have obvious restraining effect of invasion effect of the persister of the lung cancer cisplatin.

The invention provides an M1 type macrophage exosome vaccine as well as a preparation method and application thereof. The M1 type macrophage exosome vaccine is characterized in that an exosome vaccine M1Ag-Exos is obtained by enabling M1 type macrophages to uptake a specific tumor antigen Ag and then extracting an exosome of the M1 type macrophages carrying the tumor antigen Ag. According to the M1 type macrophage exosome vaccine, the exosome vaccine capable of adjusting the tumor immune microenvironment is constructed to enhance the immunotherapy efficiency, and polarization of tumor-related macrophages and the remarkable immune activation effect of a tumor vaccine are achieved through the M1 type macrophage exosome; the tumor-related macrophages are polarized into M1 type, so that the macrophages are converted from a state of promoting tumor invasion and metastasis by immunosuppression into a state of supporting tumors by immunity; meanwhile, through immunoregulation on the tumor microenvironment, the tumor vaccine can promote proliferation and activation of T cells more efficiently, and growth and metastasis of the tumors are effectively inhibited.

The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and/or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.

It has been shown that Compound 1 unexpectedly and potently inhibits TIE2 kinase, and that Compound 1 inhibits drug resistance mechanisms in both the tumor and in the surrounding microenvironment through balanced inhibition of TIE2, MET, and VEGFR2 kinases. Thus, Compound 1 provides a single therapeutic agent able to address multiple hallmarks of cancer by inhibiting TIE2, MET, and VEGFR2 kinases in the tumor microenvironment [Hanahan 2011]. Through its balanced inhibitory potency vs TIE2, MET, and VEGFR2, Compound 1 provides an agent which inhibits three major tumor (re)vascularization and resistance pathways (ANG, HGF, VEGF) and blocks tumor invasion and metastasis. Compound 1 exhibits anti-tumor activity alone and in combination with other targeted agents or chemotherapy.

The invention relates to a cholangiocarcinoma cell medicine target point. The medicine target point is ubiquitin specific protease 8, and the nucleotide sequence is shown as SEQID NO:1 in a sequence table. For the first time, the invention puts forward that USP8 is knocked down, so that proliferation, migration and invasion of cholangiocarcinoma cells can be notably restrained, MMP9 activity achieving important effects on cell adhesion, neoplasm invasiveness and transfer is reduced, and the USP8 is promoted to achieve effect of oncogene for growth and transfer ability of cholangiocarcinoma. New possibility is provided for development of cholangiocarcinoma medicines and cholangiocarcinoma prevention, treatment and prognosis.

The invention relates to the field of cancers, in particular to a biomarker beneficial to liver cancer diagnosis and prognosis, and the change level of the biomarker (transcription activator 4) in a subject sample is beneficial to liver cancer diagnosis of a subject or prognosis of a liver cancer subject. Compared with a traditional biomarker, the ATF4 protein can more comprehensively mark liver cancer cells and has obvious expression difference in liver cancer lesions, the range of the cancer lesions can be confirmed through detection, and the tumor invasion range can be judged more easily; the traditional tumor biomarker Ki67 only marks proliferative active liver cancer cells, while ATF4 protein not only can mark Ki67 positive cells, but also shows high expression in the whole liver tumor tissue compared with para-carcinoma tissue. In addition, the ATF4 protein is combined with other liver cancer biomarkers, so that cancer focuses can be positioned more accurately and comprehensively.

Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.

The invention relates to an anti-tumor combined preparation and an application thereof. The preparation comprises a percutaneous immune membrane and an immune checkpoint blocking agent. According to the invention, the percutaneous tumor immune membrane is prepared mainly based on an alcohol plasma preparation technology and an electrostatic spraying technology, and an immune checkpoint blocker iscombined for antagonizing an immunosuppression pathway in T cells and enhancing CD8+ T cell mediated tumor destruction, so that long-term protection is provided, and tumor invasion, metastasis or recurrence is prevented.